Annual EBITDA
-$156.47 M
+$167.86 M+51.76%
December 31, 2023
Summary
- As of February 8, 2025, BEAM annual EBITDA is -$156.47 million, with the most recent change of +$167.86 million (+51.76%) on December 31, 2023.
- During the last 3 years, BEAM annual EBITDA has fallen by -$28.45 million (-22.22%).
- BEAM annual EBITDA is now -118.38% below its all-time high of -$71.65 million, reached on December 31, 2019.
Performance
BEAM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$101.03 M
-$1.71 M-1.72%
September 30, 2024
Summary
- As of February 8, 2025, BEAM quarterly EBITDA is -$101.03 million, with the most recent change of -$1.71 million (-1.72%) on September 30, 2024.
- Over the past year, BEAM quarterly EBITDA has dropped by -$1.71 million (-1.72%).
- BEAM quarterly EBITDA is now -173.09% below its all-time high of $138.22 million, reached on December 31, 2023.
Performance
BEAM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$160.83 M
+$2.05 M+1.26%
September 30, 2024
Summary
- As of February 8, 2025, BEAM TTM EBITDA is -$160.83 million, with the most recent change of +$2.05 million (+1.26%) on September 30, 2024.
- Over the past year, BEAM TTM EBITDA has increased by +$2.05 million (+1.26%).
- BEAM TTM EBITDA is now -126.70% below its all-time high of -$70.94 million, reached on September 30, 2019.
Performance
BEAM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BEAM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.8% | -1.7% | +1.3% |
| 3 y3 years | -22.2% | -48.8% | +55.8% |
| 5 y5 years | -34.8% | -490.3% | -124.5% |
BEAM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +59.4% | -173.1% | +2.0% | -2.8% | +58.2% |
| 5 y | 5-year | -118.4% | +59.4% | -173.1% | +49.2% | -124.5% | +58.2% |
| alltime | all time | -118.4% | +59.4% | -173.1% | +49.2% | -126.7% | +58.2% |
Beam Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$101.03 M(+1.7%) | -$160.83 M(-1.3%) |
| Jun 2024 | - | -$99.32 M(+0.6%) | -$162.88 M(+1.2%) |
| Mar 2024 | - | -$98.70 M(-171.4%) | -$160.89 M(+2.8%) |
| Dec 2023 | -$156.47 M(-51.8%) | $138.22 M(-234.1%) | -$156.47 M(-58.8%) |
| Sep 2023 | - | -$103.08 M(+5.9%) | -$379.73 M(+4.2%) |
| Jun 2023 | - | -$97.33 M(+3.2%) | -$364.48 M(+5.4%) |
| Mar 2023 | - | -$94.28 M(+10.9%) | -$345.70 M(+6.6%) |
| Dec 2022 | -$324.33 M(-15.8%) | -$85.04 M(-3.2%) | -$324.33 M(+8.1%) |
| Sep 2022 | - | -$87.83 M(+11.8%) | -$300.14 M(+7.1%) |
| Jun 2022 | - | -$78.55 M(+7.7%) | -$280.19 M(+8.2%) |
| Mar 2022 | - | -$72.91 M(+19.8%) | -$258.95 M(-32.7%) |
| Dec 2021 | -$385.01 M | -$60.85 M(-10.4%) | -$385.01 M(+5.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$67.88 M(+18.5%) | -$363.69 M(+9.6%) |
| Jun 2021 | - | -$57.30 M(-71.2%) | -$331.91 M(+10.7%) |
| Mar 2021 | - | -$198.97 M(+403.4%) | -$299.75 M(+134.1%) |
| Dec 2020 | -$128.03 M(+78.7%) | -$39.53 M(+9.5%) | -$128.03 M(+12.4%) |
| Sep 2020 | - | -$36.10 M(+43.6%) | -$113.87 M(+20.0%) |
| Jun 2020 | - | -$25.14 M(-7.8%) | -$94.88 M(+9.6%) |
| Mar 2020 | - | -$27.25 M(+7.4%) | -$86.53 M(+20.8%) |
| Dec 2019 | -$71.65 M(-38.3%) | -$25.37 M(+48.2%) | -$71.65 M(+1.0%) |
| Sep 2019 | - | -$17.12 M(+1.9%) | -$70.94 M(-43.6%) |
| Jun 2019 | - | -$16.79 M(+35.7%) | -$125.82 M(+15.4%) |
| Mar 2019 | - | -$12.37 M(-49.8%) | -$109.02 M(+12.8%) |
| Dec 2018 | -$116.09 M | -$24.66 M(-65.7%) | -$96.65 M(+34.3%) |
| Sep 2018 | - | -$71.99 M | -$71.99 M |
FAQ
- What is Beam Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Beam Therapeutics?
- What is Beam Therapeutics annual EBITDA year-on-year change?
- What is Beam Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Beam Therapeutics?
- What is Beam Therapeutics quarterly EBITDA year-on-year change?
- What is Beam Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Beam Therapeutics?
- What is Beam Therapeutics TTM EBITDA year-on-year change?
What is Beam Therapeutics annual EBITDA?
The current annual EBITDA of BEAM is -$156.47 M
What is the all time high annual EBITDA for Beam Therapeutics?
Beam Therapeutics all-time high annual EBITDA is -$71.65 M
What is Beam Therapeutics annual EBITDA year-on-year change?
Over the past year, BEAM annual EBITDA has changed by +$167.86 M (+51.76%)
What is Beam Therapeutics quarterly EBITDA?
The current quarterly EBITDA of BEAM is -$101.03 M
What is the all time high quarterly EBITDA for Beam Therapeutics?
Beam Therapeutics all-time high quarterly EBITDA is $138.22 M
What is Beam Therapeutics quarterly EBITDA year-on-year change?
Over the past year, BEAM quarterly EBITDA has changed by -$1.71 M (-1.72%)
What is Beam Therapeutics TTM EBITDA?
The current TTM EBITDA of BEAM is -$160.83 M
What is the all time high TTM EBITDA for Beam Therapeutics?
Beam Therapeutics all-time high TTM EBITDA is -$70.94 M
What is Beam Therapeutics TTM EBITDA year-on-year change?
Over the past year, BEAM TTM EBITDA has changed by +$2.05 M (+1.26%)